KURA Share Price Performance
US$11.57
2.75 (31.10%)
62.9% undervalued intrinsic discount
US$31.17
Fair Value
Price US$11.57
AnalystConsensusTarget US$31.17
AnalystLowTarget US$15.00
AnalystHighTarget US$60.96
Fair ValueUS$31.17
Share Pricen/a
Kura Oncology, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
KURA Community Narratives
AN
Fair Value
·Fair Value US$31.17 62.9% undervalued intrinsic discount
Upcoming FDA Approval Will Open New Oncology Avenues
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value
·Fair Value US$15 22.9% undervalued intrinsic discount
Menin Inhibition Headwinds Will Challenge Oncology Outlook Yet Long-Term Prospects Remain Intact
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$60.96 81.0% undervalued intrinsic discount
Aging Populations And Precision Medicine Will Widen Oncology Frontiers
1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Kura Oncology
22.9% undervalued intrinsic discount
Menin Inhibition Headwinds Will Challenge Oncology Outlook Yet Long-Term Prospects Remain Intact
View narrativeAN
Updated 26 Aug
Kura Oncology
81.0% undervalued intrinsic discount
Aging Populations And Precision Medicine Will Widen Oncology Frontiers
View narrativeAN
Updated 23 Jun
Kura Oncology
62.9% undervalued intrinsic discount
Upcoming FDA Approval Will Open New Oncology Avenues
View narrativeAN
Updated 6 Jun
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
KURA: Early Leukemia Adoption And Insider Buying May Drive Bullish Repricing
Fair Value: US$15 22.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
KURA: Early Launch Execution In AML Will Shape Long Term Prospects
Fair Value: US$60.96 81.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
KURA: Leukemia And KRAS Trial Progress Will Shape Future Upside Potential
Fair Value: US$31.17 62.9% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Kura Oncology, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -3.34
- -236.72%
- -384.30%
- 20.2%
About KURA
- Founded
- n/a
- Employees
- 260
- CEO
- WebsiteView website
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
